Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
A Study of 1592U89 in HIV-Infected Adults Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on A Study of 1592U89 in HIV-Infected Adults conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. A Study of 1592U89 in HIV-Infected Adults Clinical research trials and A Study of 1592U89 in HIV-Infected Adults healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including A Study of 1592U89 in HIV-Infected Adults. A Study of 1592U89 in HIV-Infected Adults Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a A Study of 1592U89 in HIV-Infected Adults clinical trial. Participants typically obtain the most effective healthcare available for their A Study of 1592U89 in HIV-Infected Adults condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.

Home > "A" Clinical Trials Conditions > A Study of 1592U89 in HIV-Infected Adults

A Study of 1592U89 in HIV-Infected Adults



A Study of 1592U89 in HIV-Infected Adults

For Condition: HIV Infections
Status: Completed
Sponsor(s): Glaxo Wellcome ,
Synopsis: The purpose of this study is to see if it is safe and effective to give 1592U89 to HIV-positive adults. This study also examines the influence previous anti-HIV treatment has on the effectiveness of 1592U89.
Details: Patients receive open-label 1592U89 administered orally in combination with at least one other antiretroviral agent that the patient has not previously received.
Eligibility:
Study Type:  Interventional, Treatment, Safety Study
Minimum Age/Maximum Age: 13 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: Erythropoietin, G-CSF and GM-CSF. Patients must have: - CD4+ cell count < 100 cells/mm3. - HIV-1 RNA > 30,000 copies/ml. - Signed, informed consent from parent or legal guardian for patient under 18 years of age. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Renal failure requiring dialysis. - Hepatic failure evident by grade 3/4 hyperbilirubinemia and AST 5 times the upper limit of normal. - Documented hypersensitivity to 1592U89. - Serious medical conditions, such as diabetes, congestive heart failure, cardiomyopathy, or other cardiac dysfunction, that would compromise the safety of the patient. - Participation in or ability to participate in an enrolling study of 1592U89. Required: At least 2 nucleoside reverse transcriptase inhibitors (NRTI) and one protease inhibitor (or intolerance to one protease inhibitor and one NRTI due to trying at least 2 different regimens with at least one protease inhibitor). Alcohol or illicit drug use that may interfere with the patient's compliance.
Total Enrollment: 

Location and Contact Information:

Glaxo Wellcome Inc
Research Triangle Park,  North Carolina,  277093398
United States
 


Additional Information:
Study ID Numbers:  238M;  CNAA3008
Study Start Date: 
Record last reviewed: December 1998
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002200

Other Hiv Infections Studies:
1. A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients

2. A Randomized Phase II Study of Two Doses of Interferon alfa-2a (IFN alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3

3. A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers

4. A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease.

5. Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children with Weakened Immune Systems

Related Studies:

Other HIV Infections Clinical Trials
Other North Carolina Clinical Trials
Other Research Triangle Park Clinical Trials

A Study of 1592U89 in HIV-Infected Adults
Modify your Search

  Other HIV Infections Clinical Trials
  Other North Carolina Clinical Trials
  Other Research Triangle Park Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103